SHP099 HCl

SHP099 is a highly potent, selective and orally bioavailable small-molecule SHP2 inhibitor with an IC50 value of 0.071 μM and shows no activity against SHP1.

SHP099 HCl Chemical Structure

SHP099 HCl Chemical Structure

CAS: 2200214-93-1

Selleck's SHP099 HCl has been cited by 45 publications

Purity & Quality Control

Batch: Purity: 99.95%
99.95

Products often used together with SHP099 HCl

Omipalisib (GSK2126458)


SHP099 HCl and Omipalisib reduce tumor growth in vivo.

Bye BA, et al. bioRxiv (2023): 2023-08.

Osimertinib (AZD9291)


SHP099 HCl and Osimertinib strongly suppress p-MEK and p-ERK in PC-9 and HCC827 cells.

Kano H, et al. Mol Cancer Ther. 2021 Sep;20(9):1653-1662.

Alectinib


SHP099 HCl and Alecitinib effectively inhibit cell growth in H3122 and ABC-19 cells.

Kano H, et al. Mol Cancer Ther. 2021 Sep;20(9):1653-1662.

Trametinib (GSK1120212)


SHP099 HCl and Trametinib inhibit cell proliferation in KRAS amplified GC cells.

Wong GS, et al. Nat Med. 2018 Jul;24(7):968-977.

SX-682


SHP099 HCl and SX-682 block granulocytic myeloid-derived suppressor cells (gMDSC) immigration.

Tang KH, et al. Cancer Discov. 2022 Jan;12(1):47-61.

SHP099 HCl Related Products

Choose Selective phosphatase Inhibitors

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MGH049-1A Function assay 5 μM 14 days As a single agent, SHP099 had minimal effect on cell proliferation 29505033
MGH073-2B Function assay 5 μM 14 days As a single agent, SHP099 had minimal effect on cell proliferation 29505033
MGH065-1B Function assay 5 μM 14 days As a single agent, SHP099 had minimal effect on cell proliferation 29505033
MGH045-2A Function assay 5 μM 14 days As a single agent, SHP099 had minimal effect on cell proliferation 29505033
U2OS cells Function assay 0, 1, 3, 6, 12, 25, 50 μM SHP099 reduces pErk levels in wild-type U2OS cells. 30375388
KYSE-520 Proliferation assay 5 days inhibition of cell proliferation with an IC50 of 1.4 μM 27347692
MOLM14 Antiproliferative assay 3 days Antiproliferative activity against human MOLM14 cells after 3 days by CellTiter-Glo luminescence assay, IC50 = 0.9 μM. 29089257
Click to View More Cell Line Experimental Data

Biological Activity

Description SHP099 is a highly potent, selective and orally bioavailable small-molecule SHP2 inhibitor with an IC50 value of 0.071 μM and shows no activity against SHP1.
Targets
SHP-2 [1]
(Cell-free assay)
0.07 μM
In vitro
In vitro SHP099 shows inhibition of cell proliferation (KYSE-520 model) with an IC50 of 1.4 μM. In both phosphatase and kinase panels, no biochemical inhibitory activity is evident, suggesting that the aminopyrazine series(SHP099) is quite selective for SHP2. Moreover, SHP099 shows high solubility (>0.5 mM in pH 6.8 buffer) and high permeability with no apparent efflux in Caco-2 cells[1]. SHP099 stabilizes SHP2 in an auto-inhibited conformation. SHP099 suppresses RAS-ERK signalling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro. SHP099 only has modest activity against 5HT3 when profiled against a preclinical safety pharmacology panel representing 49 common adverse drug reaction targets. SHP099 shows no activity against SHP1, the closest homologue of SHP2 sharing 61% amino acid sequence identity, supporting its high degree of target selectivity. It inhibits p-ERK with an IC50 of ~0.25 μM in SHP2-dependent MDA-MB-468 and KYSE520 cells, but not in A2058 cells. No effect is observed on p-AKT levels across the same cells. SHP099 inhibits MAPK signalling and proliferation in RTK-dependent cells through direct on-target inhibition of SHP2[2].
Cell Research Cell lines KYSE-520 cells
Concentrations 20, 6.6, 2.2, 0.74, 0.24, 0.08, and 0.027 μM
Incubation Time 2 h
Method

KYSE-520 cells (30,000 cells/well) are grown in 96-well plate culture overnight and treated with SHP2 inhibitors at concentrations of 20, 6.6, 2.2, 0.74, 0.24, 0.08, and 0.027 μM for 2 h at 37 °C. Incubations are terminated by addition of 30 μL of lysis buffer supplied with the SureFire p-ERK assay kit.

Experimental Result Images Methods Biomarkers Images PMID
Western blot EGFR / pEGFR / GAB1 / pSHP2 / GRB2 / SOS1 pMEK / MEK / pERK / Erk pERK / Bcl-xL / p85 PARP 30605687
Growth inhibition assay Cell viability 29568093
Immunofluorescence insulin receptor 30931927
In Vivo
In vivo SHP099 shows acceptable oral exposure (5 mg/kg PO, 565 μM/h) and bioavailability (46% F). SHP099 is a potent, selective, highly soluble, orally bioavailable, and efficacious SHP2 inhibitor exhibiting dose-dependent pathway inhibition and antitumor activity in xenograft models[1]. Orally administered SHP099 shows dose-dependent anti-tumour activity in the KYSE520 xenograft model and is well tolerated[2].
Animal Research Animal Models Nude mice (Tumor Xenograft)
Dosages 10, 30, or 100 mg/kg qd
Administration by oral gavage

Chemical Information & Solubility

Molecular Weight 388.72 Formula

C16H20Cl3N5

CAS No. 2200214-93-1 SDF --
Smiles Cl.CC1(N)CCN(CC1)C2=CN=C(C(=N2)N)C3=CC=CC(=C3Cl)Cl
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 78 mg/mL ( (200.65 mM); Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 6 mg/mL

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy SHP099 HCl | SHP099 HCl supplier | purchase SHP099 HCl | SHP099 HCl cost | SHP099 HCl manufacturer | order SHP099 HCl | SHP099 HCl distributor